Areteia Therapeutics Files for IPO Following $425M Series A to Advance Oral Dexpramipexole for Eosinophilic Asthma

Feb 19, 2024 21:14 CST Updated 21:14

Areteia Therapeutics

Biopharmaceutical Manufacturer

Viking Global Investors

Global Investment Institutions

Marshall Wace

Alternative Investment Management Firm

Access Industries

Private Industrial Investment Group

GV

Google's Investment Fund

ARCH Venture Partners

Venture Capital Firms

Saturn Partners

An Investment Institution Focused on Early-Stage Innovative Enterprises

Maverick Capital

Investment Advisory Firm

Population Health Partners

Venture Capital and Private Equity Firms

Sanofi

Pharmaceutical R&D Developer

Recently, Areteia Therapeutics announced the completion of an additional $75 million Series A financing to support the expansion of its current treatment for eosinophilic asthma.The Phase III clinical development of pramipexole dihydrochloride has brought the total amount of Series A financing to 425 million US dollars. Viking Global Investors and Marshall Wace joined the original investor consortium led by Bain Capital Life Sciences, with other investors including Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.New Star! $350 Million Series A Financing to Develop Oral Asthma Therapy with Dexpramipexole）

dexpramipexole

The additional funds raised will finance a significant expansion of the ongoing Phase 3 clinical program, including enhanced clinical development in Japan and several additional global markets, expanded production activities, and further lifecycle management, including the development of a once-daily formulation.

AreteiaCreated by Population Health Partners and Knopp Biosciences.Through Phase 3 clinical trials to establish Areteia and advance Dexpramipexole, ensure commercial supply, and seek potential next-generation drugs. Knopp previously owned and conducted the early development of Dexpramipexole, contributing the lead investigational drug and related assets to Areteia in the transaction.

Reducing blood eosinophil counts can bring important clinical benefits to patients with severe eosinophilic asthma. Until now, this could only be achieved through oral steroids or injectable biologics. The prospect of an orally active eosinophil-lowering drug without the side effects of oral steroids is compelling, and the research community will enthusiastically join this significant exploration.

Based on evidence from cell cultures and human biopsies, dexpramipexole inhibits the maturation and release of eosinophils in the bone marrow, thereby reducing peripheral blood eosinophil levels. In a recent Phase 2 study in patients with moderate to severe eosinophilic asthma, treatment with dexpramipexole resulted in decreases in eosinophil levels at all tested doses (37.5 mg once daily, 75 mg once daily, or 150 mg twice daily) compared to placebo. Dexpramipexole was well-tolerated in the trial, with a balanced profile of adverse events between the treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.

Follow the official account below to see the world!